858 related articles for article (PubMed ID: 25327734)
1. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
2. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
3. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
[No Abstract] [Full Text] [Related]
4. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
5. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
6. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
7. CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.
Tang XH; Li H; Zheng XS; Lu MS; An Y; Zhang XL
Cancer Med; 2019 Oct; 8(14):6426-6436. PubMed ID: 31490008
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
10. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
[TBL] [Abstract][Full Text] [Related]
11. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
[TBL] [Abstract][Full Text] [Related]
12. [Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells].
Li ZM; Hu S; Xiao L; Wang J; Cai J; Yu LL; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):372-5. PubMed ID: 20646448
[TBL] [Abstract][Full Text] [Related]
13. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
Dateoka S; Ohnishi Y; Kakudo K
Med Mol Morphol; 2012 Jun; 45(2):91-7. PubMed ID: 22718294
[TBL] [Abstract][Full Text] [Related]
14. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
[TBL] [Abstract][Full Text] [Related]
15. [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel].
Xiao L; Gao R; Lu S; Lu MS; Liang ML; Ren LR; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):412-6. PubMed ID: 17697605
[TBL] [Abstract][Full Text] [Related]
16. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
[TBL] [Abstract][Full Text] [Related]
17. [Effect of estrogen or progesterone combined with paclitaxel on human ovarian cancer cell growth and Drosha expression].
Yang Y; Han K; Xie Y
Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):578-84. PubMed ID: 26714597
[TBL] [Abstract][Full Text] [Related]
18. [Impact of cyclin-dependent kinase inhibitor p27 on resistance of ovarian cancer multicellular spheroids to taxol].
Xing H; Li J; Gao QL; Wu JH; Gao C; Lu YP; Ma D
Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(1):37-41. PubMed ID: 12757643
[TBL] [Abstract][Full Text] [Related]
19. Octreotide reverses the resistance of A2780/Pacliaxel ovarian cancer cell line to paclitaxel chemotherapy in vitro.
Shen Y; Zhang XY; Chen X; Ren ML; Cai YL
J Cancer Res Ther; 2016; 12(2):657-62. PubMed ID: 27461627
[TBL] [Abstract][Full Text] [Related]
20. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P
Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
